AI-generated analysis. Always verify with the original filing.
Q32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on March 27, 2026, establishing an at-the-market offering program to sell up to $14,200,000 of its common stock. This agreement provides the company with a flexible mechanism to raise capital from time to time at its discretion.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 27, 2026, Q32 Bio Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “S
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Goodwin Procter LLP. 10.1 Controlled Equity Offering SM Sales Agreement,
Material Agreement